Erlotinib in non-small-cell lung cancer: A review of the clinical and economic evidence

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 9, Issue 5, 2009, Pages 409-416

  Carlson, Josh J ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cost; Cost effectiveness; Erlotinib; Lung cancer

Indexed keywords

ANTIBIOTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; LOPERAMIDE; PACLITAXEL; PEMETREXED; PLACEBO; STEROID;

ADVANCED CANCER; ANEMIA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DISEASE SEVERITY; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; GENE OVEREXPRESSION; HEALTH CARE COST; HUMAN; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; SENSITIVITY ANALYSIS; TREATMENT INDICATION;

CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; DRUG COSTS; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 70449657683     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.09.49     Document Type: Review

References (35)

1. Garcia MJA, Ward EM, Center MM, Hao Y, Siegel RL, Thun MJ. Global Cancer Facts and Figures 2007. American Cancer Society, GA, USA (2007).
2. NICE. ERG Report: Erlotinib for the Treatment of Relapsed Non-Small Cell Lung Cancer. The National Institute for Health and Clinical Excellence, Liverpool, UK (2006).
3. NCCN. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer V.1.2009. National Comprehensive Cancer Network, PA, USA (2009).
4. Ramsey SD, Howlader N, Etzioni RD, Donato B. Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results - Medicare. J. Clin. Oncol. 22(24), 4971-4978 (2004). (Pubitemid 46638623)
5. Carlson JJ, Veenstra DL, Ramsey SD. Pharmacoeconomic evaluations in the treatment of non-small cell Lung Cancer Drugs 68(8), 1105-1113 (2008).
6. NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J. Clin. Oncol. 26(28), 4617-4625 (2008).
7. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. 18(10), 2095-2103 (2000). (Pubitemid 30324363)
8. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353(2), 123-132 (2005). (Pubitemid 41058344)
9. Ramsey SD, Martins RG, Blough DK, Tock LS, Lubeck D, Reyes CM. Second-line and third-line chemotherapy for lung cancer: use and cost. Am. J. Manag. Care 14(5), 297-306 (2008). (Pubitemid 351705845)
10. Gatzemeier U, Pluzanska A, Szczesna A et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J. Clin. Oncol. 25(12), 1545-1552 (2007). (Pubitemid 46733081)
11. Herbst RS, Prager D, Hermann R et al. TRIBUTE: a Phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 23(25), 5892-5899 (2005). (Pubitemid 46300205)
12. Gridelli C, Bareschino MA, Schettino C, Rossi A, Maione P, Ciardiello F. Erlotinib in non-small cell lung cancer treatment: current status and future development. Oncologist 12(7), 840-849 (2007). (Pubitemid 47328227)
13. Gridelli C, Maione P, Rossi A et al. Potential treatment options after first-line chemotherapy for advanced NSCLC: maintenance treatment or early second-line? Oncologist 14(2), 137-147 (2009).
14. Cappuzzo F, Ciuleanu T, Stelmakh L et al. SATURN: a double-blind, randomized, Phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. J. Clin. Oncol. 27(Suppl.), 15S (2009) (Abstract 8001).
15. Miller VA, O'Connor P, Soh C, Kabbinavar F. A randomized, double-blind, placebo-controlled, Phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J. Clin. Oncol. 27(Suppl.), 18S (2009) (Abstract LBA8002).
16. Belani CP, Brodowicz T, Ciuleanu T et al. Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: a randomized Phase III study in advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 27, CRA8000 (2009).
17. Tsao MS, Sakurada A, Cutz JC et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N. Engl. J. Med. 353(2), 133-144 (2005). (Pubitemid 41058345)
18. Kim ES, Hirsh V, Mok T et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised Phase III trial. Lancet 372(9652), 1809-1818 (2008).
19. Jones D. Avastin-Tarceva combination fails in lung cancer. Nat. Biotechnol. 27(2), 108-109 (2009).
20. Silvestri G, Pritchard R, Welch HG. Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ 317(7161), 771-775 (1998). (Pubitemid 28427226)
21. Jatoi A, Nguyen PL. Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy. Oncologist 13(11), 1201-1204 (2008).
22. Eaby B, Culkin A, Lacouture ME. An interdisciplinary consensus on managing skin reactions associated with human epidermal growth factor receptor inhibitors. Clin. J. Oncol. Nurs. 12(2), 283-290 (2008).
23. Perez-Soler R, Delord JP, Halpern A et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/ EGFR inhibitor rash management forum. Oncologist 10(5), 345-356 (2005). (Pubitemid 40647253)
24. Tsuboi M, Le Chevalier T. Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitors. Med. Oncol. 23(2), 161-170 (2006). (Pubitemid 43785965)
25. Leighl NB, Tsao WS, Zawisza DL, Nematollahi M, Shepherd FA. A willingness-to-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer. Lung Cancer 51(1), 115-121 (2005).
26. van Zandwijk N. Epidermal growth factor tyrosine kinase inhibitors (EGFR TKIs) and economics. Lung Cancer 51(1), 137-138 (2006).
27. Ramsey SD, Clarke L, Kamath TV, Lubeck D. Evaluation of erlotinib in advanced non-small cell lung cancer: impact on the budget of a U.S. health insurance plan. J. Manag. Care Pharm. 12(6), 472-478 (2006). (Pubitemid 47400588)
28. Carlson JJ, Garrison LP, Ramsey SD, Veenstra DL. The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. Value Health 12(1), 20-27 (2008).
29. Carlson JJ, Reyes C, Oestreicher N, Lubeck D, Ramsey SD, Veenstra DL. Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC). Lung Cancer 61(3), 405-415 (2008).
30. Pompen M, Novak A, Postmus P. Cost-effectiveness analysis of erlotinib in the Netherlands. Value Health 9(6), A203 (2006).
31. Terres R, Sanz A, Gylmark M. Pharmacoeconomic analysis in spain of therapy with erlotinib, docetaxel, pemetrexed or best supportive care in patients with advanced nonsmall cell lung cancer who have failed previous chemotherapy regimens. Value Health 9(6), A283 (2006).
32. Lewis G, Morlotti L, Creeden J. Cost-effectiveness of erlotinib compared with docetaxel for the treatment of relapsed nonsmall cell lung cancer (NSCLC) in the UK. Value Health 9(6), A203 (2006).
33. Orlewska E, Szczesna A, Gyldmark M. Cost effectiveness of erlotinib in the treatment of advanced non small cell lung cancer (NSCLC) in poland. Value Health 9(6), A280 (2006).
34. Côté I, Leighl N, Gyldmark M, Maturi B. Pharmacoeconomic analyses of erlotinib compared with best supportive care (BSC) for the treatment of relapsed non-small cell lung cancer (NSCLC) from the canadian public health care perspective. Value Health 9(6), A279 (2006).
35. ClinicalTrials.gov http://clinicaltrials.gov/ct2/home (Accessed 19 June 2009)